Scarica l'app Stockscreener
71.63
0.14%
0.10
Dopo l'orario di chiusura:
71.63
Avidity Biosciences Inc Borsa (RNA) Ultime notizie
Avidity Biosciences (NASDAQ:RNA) Reaches New 52-Week HighStill a Buy? - MarketBeat
JPMorgan Chase & Co. Buys 139,473 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences stock hits all-time high at 71.78 USD - Investing.com
Avidity Biosciences stock hits all-time high at 71.78 USD By Investing.com - Investing.com Australia
Why Avidity Biosciences Inc. stock could benefit from AI revolution2025 Breakouts & Breakdowns & Free Expert Approved Momentum Trade Ideas - Newser
Avidity Biosciences, Inc. (RNA): A Bull Case Theory - Finviz
Schroder Investment Management Group Raises Stake in Avidity Biosciences, Inc. $RNA - MarketBeat
How Avidity Biosciences Inc. stock reacts to Fed rate cutsEarnings Overview Summary & AI Enhanced Trade Execution Alerts - Newser
Avidity Biosciences, Inc. $RNA Shares Sold by Steward Partners Investment Advisory LLC - MarketBeat
Avidity Biosciences, Inc. $RNA Shares Sold by Prudential Financial Inc. - MarketBeat
Will Avidity Biosciences Inc. stock outperform Dow Jones indexMarket Growth Report & Detailed Earnings Play Alerts - Newser
Creative Planning Grows Stock Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44 (PR Newswire) - Aktiellt
Discipline and Rules-Based Execution in RNA Response - news.stocktradersdaily.com
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 (PR Newswire) - Aktiellt
Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society (PR Newswire) - Aktiellt
Update Recap: Can Avidity Biosciences Inc. stock sustain free cash flow growth2025 Risk Factors & Reliable Entry Point Alerts - BỘ NỘI VỤ
What analysts say about Avidity Biosciences Inc stockSwing Trading Watchlist & Investment Timing Techniques - earlytimes.in
SG Americas Securities LLC Raises Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights (PR Newswire) - Aktiellt
Avidity Biosciences, Inc. $RNA Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis - MSN
Avidity Played Hardball to Land Favorable Terms in $12B Novartis Deal - BioSpace
Avidity Biosciences (NASDAQ:RNA) Reaches New 12-Month HighStill a Buy? - MarketBeat
Avidity Biosciences stock hits all-time high at 71.1 USD By Investing.com - Investing.com Nigeria
Avidity Biosciences stock hits all-time high at 71.1 USD - Investing.com
Avidity Biosciences, Inc. $RNA Shares Sold by Intech Investment Management LLC - MarketBeat
Halper Sadeh LLC Encourages WTRG, RNA, TCBX Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Avidity Biosciences Inc. (RNA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Avidity Biosciences Inc Stock Analysis and ForecastStochastic Oscillator Alerts & Rapid Capital Trading - earlytimes.in
How Avidity Biosciences Inc. stock trades during market volatilityMarket Rally & Reliable Breakout Forecasts - newser.com
How Avidity Biosciences Inc. stock performs after earnings2025 Market Trends & Daily Growth Stock Investment Tips - newser.com
Key facts: Novartis to Acquire Avidity for $12B; Raises Sales Guidance - TradingView
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44 - BioSpace
Will Avidity Biosciences Inc. stock deliver long term returns2025 Market Outlook & Long-Term Safe Return Strategies - newser.com
Price action breakdown for Avidity Biosciences Inc.Quarterly Profit Review & Expert Approved Momentum Ideas - newser.com
Is Avidity Biosciences Inc. showing signs of accumulationBreakout Watch & Low Drawdown Momentum Ideas - newser.com
Using AI based signals to follow Avidity Biosciences Inc.Quarterly Portfolio Review & Technical Analysis for Trade Confirmation - newser.com
Will Avidity Biosciences Inc. stock attract more institutional investorsIndex Update & Community Shared Stock Ideas - newser.com
What Wall Street predicts for Avidity Biosciences Inc. stock priceRate Cut & Low Drawdown Trading Techniques - newser.com
What to expect from Avidity Biosciences Inc. in the next 30 daysWeekly Investment Report & Low Drawdown Momentum Ideas - newser.com
Avidity launches managed access program for DMD44 therapy By Investing.com - Investing.com Nigeria
Looking Into Avidity Biosciences Inc's Recent Short Interest - Benzinga
Avidity Biosciences announces U.S. Managed Access Program (MAP) for investigational therapy del-zota in DMD44 - MarketScreener
Avidity Biosciences Announces U.S. Managed Access Program for Investigational Therapy del-zota in DMD44 - Investing News Network
Avidity launches managed access program for DMD44 therapy - Investing.com
Avidity Biosciences (Nasdaq: RNA) launches del-zota MAP in DMD44, plans 2026 BLA filing - Stock Titan
Can Avidity Biosciences Inc. stock deliver sustainable ROEMarket Movement Recap & Safe Entry Momentum Tips - newser.com
Heatmap analysis for Avidity Biosciences Inc. and competitorsJuly 2025 Spike Watch & Low Volatility Stock Recommendations - newser.com
Detecting support and resistance levels for Avidity Biosciences Inc.Watch List & Daily Market Momentum Tracking - newser.com
1.44%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):